Kindred Biosciences (KIN) 10-Q2021 Q1 Quarterly report

Filed: 11 May 21, 4:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ago, alpha, analytical, attain, attained, Banfield, board, broad, Canadian, Cancer, cGMP, checkpoint, CIBDAI, collaboration, confirmed, contractor, convenience, deadline, decision, demand, diagnosed, director, durable, Elanco, element, Europe, exploratory, factor, formulation, frequency, gastrointestinal, Index, Institute, interleukin, interval, licensee, longer, margin, medical, National, NCI, obsolete, output, package, Parvo, patient, pattern, pet, pharmacokinetic, pool, portion, post, Preclinical, predominant, predominantly, promote, pruritic, put, remission, replace, scale, Screening, segment, selected, settled, showed, slightly, solicitation, specialty, spend, strong, sublease, submission, sum, tract, Trademark, tumor, unapproved, undiagnosed, unmet, untreated, unveiled, unwilling, visit

Removed: acceleration, acquisition, adult, advantage, adverse, afflict, agent, alongside, amortized, anemia, appetite, behavioral, borrowing, build, case, categorized, checkmark, China, Codification, colic, collectively, competitive, Concurrent, conducted, convertible, creation, CVP, declare, depending, disposal, dollar, downturn, earliest, engineered, Food, found, fourth, gastric, gel, greatest, growing, half, immunogenic, inclusion, India, invoice, kidney, legal, lender, lien, monthly, occurrence, organization, partial, path, percent, preferred, prepay, prepayment, prioritized, produce, prolonged, proprietary, rapidly, raw, recombinant, red, reflecting, schedule, shown, shutdown, size, subordinated, successful, syndrome, tranche, transportation, ulcer, unrestricted, variety, weight, working, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated KIN transcripts

KIN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

AND THE CHIEF FINANCIAL OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Kindred Biosciences, Inc. (the “Company”) hereby certifies that, to his or her knowledge:

(i) The quarterly report on Form 10-Q for the period ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 11, 2021	By: /s/ Richard Chin	By: /s/ Wendy Wee
	Name: Richard Chin, MD	Name: Wendy Wee
	Title: Chief Executive Officer	Title: Chief Financial Officer